Last reviewed · How we verify

Sofosbuvir-Ribavirin — Competitive Intelligence Brief

Sofosbuvir-Ribavirin (Sofosbuvir-Ribavirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide polymerase inhibitor + nucleoside analog antiviral. Area: Virology / Hepatology.

marketed Nucleotide polymerase inhibitor + nucleoside analog antiviral HCV NS5B RNA-dependent RNA polymerase; ribavirin has multiple targets Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Sofosbuvir-Ribavirin (Sofosbuvir-Ribavirin) — Ain Shams University. Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, while ribavirin is a nucleoside analog that enhances viral suppression through multiple mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sofosbuvir-Ribavirin TARGET Sofosbuvir-Ribavirin Ain Shams University marketed Nucleotide polymerase inhibitor + nucleoside analog antiviral HCV NS5B RNA-dependent RNA polymerase; ribavirin has multiple targets

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide polymerase inhibitor + nucleoside analog antiviral class)

  1. Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofosbuvir-Ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-ribavirin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: